Trepipam (INN) is a dopamine receptor agonist of the benzazepine group that was never marketed.[1] It acts specifically as an agonist of the dopamine D1 receptor.[2] It is closed related structurally to fenoldopam, a peripherally acting selective D1 receptor partial agonist which is used as an antihypertensive agent.

References

  1. ^ Lednicer D (4 March 2009). Strategies for Organic Drug Synthesis and Design. John Wiley & Sons. pp. 495–. ISBN 978-0-470-39959-0.
  2. ^ Goode-Romero G, Winnberg U, Domínguez L, Ibarra IA, Vargas R, Winnberg E, Martínez A (December 2020). "New information of dopaminergic agents based on quantum chemistry calculations". Sci Rep. 10 (1): 21581. Bibcode:2020NatSR..1021581G. doi:10.1038/s41598-020-78446-4. PMC 7725812. PMID 33299000.